Sequential use of infliximab and etanercept in generalized pustular psoriasis

Cutis

Volumn 78, Issue 3, 2006, Pages 197-199

  Weisenseel, Peter ^a   Prinz, Jörg Christoph ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BULLOUS SKIN DISEASE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PSORIASIS;

ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, VESICULOBULLOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749255411     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Tobin AM, Kirby B. TNF-alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19:47-57.
2. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49(suppl 2):S112-S117.
3. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
4. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34:161-164.
5. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41:449-452.
6. Kamarashev J, Lor P, Forster A, et al. Generalized pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213-216.
7. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15:280-294.